Monoclonality

Global Therapeutic Antibody Market Forecast to Reach USD 428.20 Billion by 2029: In-Depth Analysis by Antibody Type, Source, and Application - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Pharmaceutical, Health, Prevalence, Application, SWOT, Monoclonality, COVID-19, Conditional sentence, Monoclonal antibody, Vaccine

Global Therapeutic Antibody Market reveals significant insights into market segmentation, including monoclonal antibodies, bispecific antibodies, and more.

Key Points: 
  • Global Therapeutic Antibody Market reveals significant insights into market segmentation, including monoclonal antibodies, bispecific antibodies, and more.
  • This in-depth report examines the forecast growth trends and market dynamics from 2024 to 2029, with a specific focus on key regions and countries contributing to the global market expansion.
  • The market is analyzed by product type, source, and application, offering a thorough understanding of the therapeutic antibody landscape.
  • Through a careful examination of industry trends, drivers, and challenges, the report provides an insightful forecast and analysis that bolsters understanding of the Global Therapeutic Antibody Market's future trajectory.

Global CD137 Antibodies Clinical Trials Research Report 2023: Insights on More Than 60 CD137 Antibodies in Clinical Trials - ResearchAndMarkets.com

Retrieved on: 
Monday, June 5, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Lymphoma, Monoclonal antibody, TNF, Prevalence, Anticalin, CD3, HER2, Roche, Indication, Cancer, NK, CD137, Bristol Myers Squibb, GNC, Antibody, Lung cancer, Monoclonality, Hematological Cancer Research Investment and Education Act, CD137L, Protein, Patient, Drug combination, Compass, Urelumab, Observation, Merck, Leukemia, Therapy, Pembrolizumab, Stomach, PD-L1, Family, Vaccine, Pharmaceutical industry, Pfizer

The "Global CD137 Antibodies Clinical Trials & Market Trends Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD137 Antibodies Clinical Trials & Market Trends Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • The therapeutic potential of CD137 has been investigated exhaustively and has now been confirmed as studies from running clinical and research studies emerge.
  • Utomilumab and Urelumab were among the first CD137 agonists to be developed and introduced in human clinical trials.
  • Global CD137 Antibodies Clinical Trials Insight by Company, Indication & Phase
    CD137 Therapeutic Approaches by Monoclonal, Bispecific, Trispecific & Tetraspecific Antibodies

Global Custom Antibody Market Report to 2030: Increasing Demand for Customized Diagnostics and Therapeutics Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, May 22, 2023
Health, Pharmaceutical, Mouse, Central nervous system, Sigma-Aldrich, Neoplasm, Infection, Cancer, Antibody, Research, Monoclonality, USD, ATRX, Incidence, Developed country, Application, Engineering, Growth, Neuropathology, Glioma, Fine chemical, Vaccine, Pharmaceutical industry

The global custom antibody market size is expected to reach USD 301.7 million by 2030, expanding at a CAGR of 9.7% from 2023 to 2030.

Key Points: 
  • The global custom antibody market size is expected to reach USD 301.7 million by 2030, expanding at a CAGR of 9.7% from 2023 to 2030.
  • Additionally, rising awareness of personalized diagnostic and therapeutic treatments in emerging markets is also a contributing factor to the growth of the custom antibody market.
  • However, the high cost of producing custom monoclonal antibodies is expected to restrain the growth of the custom antibody market.
  • The increasing R&D investment by companies is expected to support the growth of the custom antibody market
    By service, the antibody development segment captured the majority of the custom antibody market share in 2022.

Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI

Retrieved on: 
Thursday, May 11, 2023
NRTI, HDV, Hepatitis B virus, Inflammation, Monoclonality, Small RNA, SAN, Clinical research, HBV, Safety, Pharmaceutical industry, Vaccine

SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 STRIVE sub-protocol clinical trial evaluating the safety and efficacy of regimens containing combinations of VIR-3434, VIR-2218, pegylated interferon alpha (PEG-IFNα) and a nucleoside reverse transcriptase inhibitor (NRTI) in hepatitis B virus (HBV) immune-active, treatment-naïve adults. The STRIVE sub-protocol trial is the first to initiate under Vir’s new PREVAIL platform trial evaluating VIR-2218 and VIR-3434 with other therapies, including PEG-IFNα and an NRTI, in people at various stages of chronic HBV infection. Initial data from the STRIVE sub-protocol trial are expected in the first half of 2024.

Key Points: 
  • The STRIVE sub-protocol trial is the first to initiate under Vir’s new PREVAIL platform trial evaluating VIR-2218 and VIR-3434 with other therapies, including PEG-IFNα and an NRTI, in people at various stages of chronic HBV infection.
  • Initial data from the STRIVE sub-protocol trial are expected in the first half of 2024.
  • Under the PREVAIL platform trial, the THRIVE sub-protocol trial will evaluate the safety and efficacy of regimens containing VIR-3434 and an NRTI with or without VIR-2218.
  • VIR-2218 and VIR-3434 are also being evaluated for the treatment of chronic HBV in adults who are already virally suppressed by an NRTI in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial.

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, March 14, 2023
CGEM, New Drug Application, AACR, Inhibitor, Monoclonality, Patient, FDA, Immunoglobulin G, Medical imaging, Pharmaceutical industry, Paint

CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc., (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that posters of preclinical data highlighting the therapeutic potential of two assets, CLN-619 and CLN-617, will be presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, Florida, April 14-17, 2023.

Key Points: 
  • Initial clinical data from the ongoing trial is on-track to be released mid-2023.
  • CLN-617 is a cytokine therapy combining IL-2 and IL-12 in a single molecule.
  • CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc., (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that posters of preclinical data highlighting the therapeutic potential of two assets, CLN-619 and CLN-617, will be presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando, Florida, April 14-17, 2023.
  • “While distinct programs, each has the potential to be a first- and/or best-in-class therapy across a broad range of solid tumor types.

The Executive Talk by ShareInvestor: Rojukiss International PCL (SET: KISS)

Retrieved on: 
Friday, November 4, 2022
Pillar, Infection, Beauty, Research, COVID-19, Growth, Sale, Government Pharmaceutical Organization, Nasal cavity, Institute, HPMC, Industry, Antibody, Executive, Faculty, KISS, Silpakorn University, Monoclonality, Neutralizing antibody, Human, PCL, Korea, GPO, Consumer, Chulalongkorn University, Volunteering, SET, HIB, Patient, Immunity, Communication, Pharmaceutical industry, Sales, Retail, Vaccine, Public relations, Medicine

Rojukiss International PCL Chief Executive Officer, Ms. Worrawan Chaikamnerd

Key Points: 
  • Rojukiss International PCL Chief Executive Officer, Ms. Worrawan Chaikamnerd
    1.
  • The priority is to grow and strengthen our core brand - the Rojukiss brand by enhancing the product innovation.
  • As a result, Rojukiss has continued to grow despite the challenging business environment amid the slow trending of Covid-19 pandemic.
  • On behalf of Rojukiss International Pcl, we will continue to develop products through innovations and with latest technologies under ethical business practices and good corporate governance.

Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection

Retrieved on: 
Thursday, September 22, 2022
Adult, Half-life, Safety, COVID-19, Sirna, Risk, Virus, Blood, ALT, U.S. Securities and Exchange Commission, HBsAg, Week, Coinfection, Viremia, Liver cancer, Private Securities Litigation Reform Act, Hepatitis B, HBV, Forward-looking statement, Alanine transaminase, Patient, Clinical trial, Drug development, Disease, Hepatitis B virus, Technology, HIV, Therapeutic index, Viral hepatitis, RNA, Research, GLOBE, Hepatocyte, HDV, Superinfection, Mortality, Immune system, Monoclonality, Infection, Death, Hepatocellular carcinoma, Vaccine, Pharmaceutical industry

SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic hepatitis D virus (HDV), which occurs as a simultaneous co-infection or super-infection alongside hepatitis B virus (HBV). HDV infection, the most aggressive form of viral hepatitis, increases the risk of poor outcomes, including liver cancer and death, compared with HBV alone.

Key Points: 
  • VIR-2218 and VIR-3434 are currently being evaluated for the treatment of HBV in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial.
  • Chronic hepatitis D virus (HDV) infection occurs as a simultaneous co-infection or super-infection with hepatitis B virus (HBV).
  • Chronic hepatitis B virus (HBV) infection remains an urgent global public health challenge associated with significant morbidity and mortality.
  • Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus.

Global Biosimilars Market Report 2022: Major Patent Expirations Fueling Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 15, 2022
Health, Other Health, Samsung Biologics, COVID-19, FDA, Growth, Autoimmune disease, Insulin, Novartis, Industry, Government, Stada Arzneimittel, USD, Laboratory, Oncology, Degenerative disease, Neglected tropical disease research and development, Filgrastim, Amgen, API, MEA, Celltrion, Eli Lilly, Mergers and acquisitions, Lists of countries and territories, Monoclonality, Pfizer, Renewable energy, Generic drug, Application, Pegfilgrastim

The Global Biosimilars Market was valued at USD 16.48 Billion in the year 2021 with the Europe region leading the regional market share.

Key Points: 
  • The Global Biosimilars Market was valued at USD 16.48 Billion in the year 2021 with the Europe region leading the regional market share.
  • Biosimilars provide relief to the healthcare infrastructure of several developing countries and are anticipated to impel market growth in the forecast period.
  • The Asia Pacific is the fastest growing market in the biosimilars market as countries within the region are providing opportunities to grow and sell medicines.
  • The Global Biosimilars Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).

Global Graft Versus Host Disease Treatment Market 2022-2027: Rising Number of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplants Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, August 29, 2022
Health, Stem Cells, Market development, USD, Ansoff Matrix, GVHD, Preventive healthcare, Investment, Monoclonality, Geography, Graft-versus-host disease, MTOR, SWOT, CAGR, Risk, Growth, Industry, Pharmaceutical industry, Etanercept, Thalidomide

The Global Graft Versus Host Disease Treatment Market is segmented based on Disease Type, Product, and Geography.

Key Points: 
  • The Global Graft Versus Host Disease Treatment Market is segmented based on Disease Type, Product, and Geography.
  • By Disease Type, the market is classified into Acute graft vs host disease, Chronic graft vs host disease, and Prophylaxis GVHD.
  • The report presents a detailed Ansoff matrix analysis for the Global Graft Versus Host Disease Treatment Market.
  • The analyst analyses the Global Graft Versus Host Disease Treatment Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Biosimilars Market to Reach $143.6 Bn, Globally, by 2031 at 24.7% CAGR: Allied Market Research

Retrieved on: 
Thursday, July 7, 2022
Monoclonality, Erythropoietin, Blood, Human, COVID-19, Growth, Growth hormone, Cancer, Industry, Degenerative disease, Prevalence, Hematologic disease, Insulin, CAGR, Vaccine, Fine chemical

PORTLAND, Ore., July 7, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Biosimilars Market by Type (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Granulocyte-Colony Stimulating Factor, Others), by Application (Blood disorders, Oncology diseases, Chronic and autoimmune diseases, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global biosimilars industry was estimated at $15.9 billion in 2021, and is anticipated to hit $143.6 billion by 2031, registering a CAGR of 24.7% from 2022 to 2031.

Key Points: 
  • "According to the report, the global biosimilars industry was estimated at $15.9 billion in 2021, and is anticipated to hit $143.6 billion by 2031, registering a CAGR of 24.7% from 2022 to 2031.
  • Increase in incidences of diabetesand autoimmune diseases drives the growth of the global biosimilars market.
  • The COVID-19 pandemic created difficulties for the pharmaceutical industry to focus on R&D activities including biosimilar development, which impacted the global biosimilars market negatively.
  • Based on region, Europe held the major share in 2021, generating nearly two-fifths of the global biosimilars market.